4-Quinolone-3-Carboxamide Furan CB2 Agonisthigh-affinity ligand of CB2 |
Sample solution is provided at 25 µL, 10mM.
Quality Control & MSDS
- View current batch:
- Purity = 98.00%
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
4-Quinolone-3-Carboxamide Furan CB2 Agonist Dilution Calculator
calculate
4-Quinolone-3-Carboxamide Furan CB2 Agonist Molarity Calculator
calculate
Cas No. | 1314230-75-5 | SDF | Download SDF |
Synonyms | 4Q3C CB2 Agonist | ||
Chemical Name | 6-(2-furanyl)-1,4-dihydro-8-methoxy-4-oxo-1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-3-quinolinecarboxamide | ||
Canonical SMILES | O=C(C1=CN(CCCCC)C2=C(C=C(C3=CC=CO3)C=C2OC)C1=O)N[C@@]45CC6C[C@H](C5)C[C@H](C4)C6 | ||
Formula | C30H36N2O4 | M.Wt | 488.6 |
Solubility | ≤30mg/ml in ethanol;3mg/ml in DMSO;3mg/ml in dimethyl formamide | Storage | Store at -20°C |
Physical Appearance | A crystalline solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. |
Ki: 8.5 nM
4-Quinolone-3-Carboxamide Furan CB2 Agonist is a high-affinity ligand of CB2.
The endocannabinoid system consists of endogenous cannabinoids (endocannabinoids), cannabinoid receptors (primarily CB1 and CB2), and the enzymes that synthesize and degrade endocannabinoids.
In vitro: Previous study found that 4-Quinolone-3-Carboxamide Furan CB2 Agonist (4g) was devoid of any potential “indirect” agonist activity at cannabinoid receptors, exerted by prolonging the lifespan of endocannabinoids because 4g at up to a 10 μM concentration did not inhibit anandamide or 2-AG degradation by FAAH or MAGL, respectively. In cytotosicity study, 4g was tested at 1 μM and the results showed that it exhibited very low or no cytotoxicity, the cell viability being above 95% after a 72 h treatment [1].
In vivo: In animal study, 4g was found to have antinociceptive activity in the formalin test in mice. Moreover, 4g was very potent with maximal effect being reached at the 1 mg/kg dose and efficacious also on the first phase of the nocifensive response. The effect of 4g could be strongly reduced by the addition of AM630, a CB2-selective antagonist/inverse agonist, therefore demonstrating that 4g might act as a potent and selective CB2 agonist [1].
Clinical trial: Up to now, 4-Quinolone-3-Carboxamide Furan CB2 Agonist is still in the preclinical development stage.
Reference:[1] S. Pasquini, M. De Rosa, V. Pedani, et al. Investigations on the 4-quinolone-3-carboxylic acid motif. 4. Identification of new potent and selective ligands for the cannabinoid type 2 receptor with diverse substitution patterns and antihyperalgesic effects in mice. Journal of Medicinal Chemistry 54, 5444-5453 (2011).